BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29159346)

  • 1. Peramivir analogues bearing hydrophilic side chains exhibit higher activities against H275Y mutant than wild-type influenza virus.
    Chiu DC; Lin TC; Huang WI; Cheng TJ; Tsai KC; Fang JM
    Org Biomol Chem; 2017 Nov; 15(46):9910-9922. PubMed ID: 29159346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peramivir conjugates as orally available agents against influenza H275Y mutant.
    Wang PC; Chiu DC; Jan JT; Huang WI; Tseng YC; Li TT; Cheng TJ; Tsai KC; Fang JM
    Eur J Med Chem; 2018 Feb; 145():224-234. PubMed ID: 29324342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
    Wang PC; Fang JM; Tsai KC; Wang SY; Huang WI; Tseng YC; Cheng YS; Cheng TJ; Wong CH
    J Med Chem; 2016 Jun; 59(11):5297-310. PubMed ID: 27167096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
    Bromba CM; Mason JW; Brant MG; Chan T; Lunke MD; Petric M; Boulanger MJ; Wulff JE
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7137-41. PubMed ID: 22001088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
    Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
    ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peramivir binding affinity with influenza A neuraminidase and research on its mutations using an induced-fit docking approach.
    Tran-Nguyen VK; Le MT; Tran TD; Truong VD; Thai KM
    SAR QSAR Environ Res; 2019 Dec; 30(12):899-917. PubMed ID: 31645133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
    Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
    Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S
    Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
    Farooqui A; Huang L; Wu S; Cai Y; Su M; Lin P; Chen W; Fang X; Zhang L; Liu Y; Zeng T; Paquette SG; Khan A; Kelvin AA; Kelvin DJ
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7255-64. PubMed ID: 26369969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
    Sriwilaijaroen N; Magesh S; Imamura A; Ando H; Ishida H; Sakai M; Ishitsubo E; Hori T; Moriya S; Ishikawa T; Kuwata K; Odagiri T; Tashiro M; Hiramatsu H; Tsukamoto K; Miyagi T; Tokiwa H; Kiso M; Suzuki Y
    J Med Chem; 2016 May; 59(10):4563-77. PubMed ID: 27095056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
    Reina J
    Rev Esp Quimioter; 2006 Dec; 19(4):317-22. PubMed ID: 17235399
    [No Abstract]   [Full Text] [Related]  

  • 15. The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.
    Abed Y; Fage C; Checkmahomed L; Begin G; Carbonneau J; Lague P; Boivin G
    Antiviral Res; 2019 Oct; 170():104561. PubMed ID: 31323237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
    Bantia S; Upshaw R; Babu YS
    Antiviral Res; 2011 Sep; 91(3):288-91. PubMed ID: 21722670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors.
    Hong BT; Chen CL; Fang JM; Tsai KC; Wang SY; Huang WI; Cheng YE; Wong CH
    Bioorg Med Chem; 2014 Dec; 22(23):6647-6654. PubMed ID: 25456388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
    Babu YS; Chand P; Bantia S; Kotian P; Dehghani A; El-Kattan Y; Lin TH; Hutchison TL; Elliott AJ; Parker CD; Ananth SL; Horn LL; Laver GW; Montgomery JA
    J Med Chem; 2000 Sep; 43(19):3482-6. PubMed ID: 11000002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.